Hemab Therapeutics 控股 COAG

John Maraganore, Ph.D. has served as chair of our board of directors since January 2022. Dr. Maraganore has served as the co-chief executive officer at Corsera Health, Inc., a privately-held clinical-stage cardiovascular company, since September 2025. He has also served as a Senior Advisor at Jefferies Financial Services, an investment banking and capital markets firm, since November 2024, a Venture Advisor at Atlas Venture, an early-stage venture capital firm, since January 2022, a Senior Advisor at Blackstone Life Sciences, a private equity investment strategy firm, since January 2022, an Executive Partner at RTW Investments, LP, a life sciences investment and innovation firm, since January 2022, a principal and Chief Executive Officer of JMM Innovations, LLC, a biotechnology strategic advisory practice, since January 2022, and a Venture Partner at ARCH Venture Partners, an early stage venture capital firm, since October 2021. Previously, Dr. Maraganore served as the founding Chief Executive Officer and a member of the board of directors of Alnylam from December 2002 to December 2021, and as President of Alnylam from December 2002 to December 2007. Dr. Maraganore has been a member of the boards of directors of Rapport Therapeutics, Inc. since March 2024, Takeda Pharmaceutical Company Limited since June 2022, Kymera Therapeutics, Inc. since February 2022 and Beam Therapeutics Inc. since November 2021, which are all biopharmaceutical companies. He also previously served on the boards of directors of ProKidney Corp. from August 2022 to May 2024 and Agios Pharmaceuticals, Inc. from June 2010 to May 2023. Dr. Maraganore holds an M.S. and a Ph.D. in Biochemistry and Molecular Biology and a B.A. in Biological Sciences from the University of Chicago.

On September 24, 2026,the Board of Directors of Hemab Therapeutics Holdings, Inc. , the Board elected Keli Walbert to serve as a member of the Board, effective immediately.

Catherine Madigan, M.D. has served as our chief medical officer since January 2025. Prior to that, Dr. Madigan served as Chief Medical Officer at Syndax Pharmaceuticals, Inc., a biopharmaceutical company, from March 2022 to December 2024. Previously, Dr. Madigan served as Vice President, Head of Clinical Development at Syros Pharmaceuticals, Inc., a biopharmaceutical company, from June 2019 to February 2022. Prior to that, she served as Senior Medical Director, Clinical Research at Alnylam from March 2018 to June 2019 and as Medical Director from June 2016 to March 2018. Dr. Madigan also was a Medical Director in the Rare Disease Innovation Unit of Biogen Inc., a biotechnology company, from February 2016 to May 2016 and served as Associate Medical Director from January 2014 to January 2016. Dr. Madigan previously held various academic positions of increasing responsibility at the University of California San Diego/Rady Children's Hospital San Diego. Dr. Madigan holds an M.D. from the Keck School of Medicine of the University of Southern California and a B.A. in Asian Studies from Dartmouth College.

Benny Sorensen, M.D., Ph.D. has served as our president and chief executive officer since July 2021 and as a member of our board of directors since November 2021. Prior to that, Dr. Sorensen served as Senior Vice President, Strategic Projects at Codiak Biosciences, Inc., or Codiak, a biopharmaceutical company, from October 2016 to July 2021. Previously, Dr. Sorensen served as Senior Director of Clinical Research at Alnylam Pharmaceuticals, Inc., or Alnylam, a biopharmaceutical company, from October 2013 to October 2016. From May 2012 to October 2013, Dr. Sorensen served as a Global Medical Director at Baxter Healthcare Corporation, or Baxter, a medical equipment manufacturing company. Prior to Baxter, Dr. Sorensen was the Director of the Haemostasias Research Unit and Honorary Lecturer at Guy's and St. Thomas' Hospital and King's College London School of Medicine. Dr. Sorensen previously served on the Scientific Advisory Board of Codiak from July 2021 to March 2023. He also served as an Associate Professor of Thrombosis and Haemostasis at Aarhus University, Denmark from 2007 until 2016. Dr. Sorensen holds an M.D. and Ph.D. from Aarhus University.

Mads Behrndt-Eriksen, M.Sc. has served as our chief financial officer and general manager since September 2021. Prior to that, Mr. Behrndt served in roles of increasing responsibility, including as a Partner, in PricewaterhouseCoopers' Corporate Finance practice from 2007 to September 2021. Mr. Behrndt holds an M.Sc. in Finance & Strategic and a B.Sc. in Economics and Business Administration Management from the Copenhagen Business School.

Ananthram Murthy, Ph.D., M.Sc. has served as our chief operating officer since September 2025. Prior to that, Dr. Murthy served as General Manager of Europe, the Middle East and Africa at argenx SE, a biotechnology company, from December 2020 to April 2025. From February 2017 to December 2020, Dr. Murthy served as Vice President, General Manager, Midsize EU Markets & Canada, and Vice President, Market Access, Pricing & Policy at Alnylam. From December 2012 to February 2017, Dr. Murthy served as Head of Pricing & Market Access at ARIAD Pharmaceuticals, Inc., a pharmaceutical company, which was acquired by Takeda Pharmaceutical Company Limited in February 2017. He also served in roles of increasing responsibility, including as Executive Director, Global Pricing & Market Access, at Celgene Corporation, or Celgene, a biopharmaceutical company, which was acquired by Bristol-Myers Squibb Company in November 2019, from October 2008 to December 2012. Prior to Celgene, Dr. Murthy was a Reimbursement Manager at Medtronic plc, a medical device company, from June 2005 to October 2008. Earlier in his career, Dr. Murthy served as a health economics and policy consultant at several private, public and non-profit organizations and held roles at Johnson & Johnson and Ernst & Young. From February 2001 to August 2002, Dr. Murthy also served as a Legislative Advisor at the U.S. Congress. Dr. Murthy holds a Ph.D. in Health Systems from the Johns Hopkins Bloomberg School of Public Health, an M.Sc. in International Health Policy from the London School of Economics and a B.A. in Health and Society and Political Science from the University of Rochester.